Evidence map›Paper›PMID 32378446›Full record

ArticleJournal of the American Heart Association2020

Localized Antileptin Therapy Prevents Aortic Root Dilatation and Preserves Left Ventricular Systolic Function in a Murine Model of Marfan Syndrome.

Sudeshna Fisch, Noa Bachner-Hinenzon, Offir Ertracht, Liang Guo, Yhara Arad, Danny Ben-Zvi, Ronglih Liao, Jacob Schneiderman

Open access · goldAbstract read
In one paragraph

Article in Journal of the American Heart Association, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Leptin antagonism improves Rett syndrome phenotype in symptomatic Mecp2-deficient mice.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 2 countries.

Sudeshna FischCardiovascular Physiology Core Department of Medicine Brigham and Women's Hospital Harvard Medical School Boston MA.
Noa Bachner-HinenzonEpidemiology Unit Rambam Health Care Center Haifa Israel.
Offir ErtrachtEliachar Research Laboratory Galilee Medical Center Nahariya Israel.
Liang GuoCVPath Institute Gaithersburg MD.
Yhara AradDepartment of Developmental Biology and Cancer Research Institute of Medical Research Israel-Canada Hebrew University of Jerusalem-Hadassah Medical School Jerusalem Israel.
Danny Ben-ZviDepartment of Developmental Biology and Cancer Research Institute of Medical Research Israel-Canada Hebrew University of Jerusalem-Hadassah Medical School Jerusalem Israel.
Ronglih LiaoCardiovascular Physiology Core Department of Medicine Brigham and Women's Hospital Harvard Medical School Boston MA.
Jacob SchneidermanDepartment of Vascular Surgery Sheba Medical Center Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel.
Hebrew University of Jerusalem · ILCVPath Institute · USHarvard University · USRambam Health Care Campus · ILSheba Medical Center · ILStanford University · USWestern Galilee Hospital · IL

Funding

VectorP30CA006516 · NCI · DANA-FARBER CANCER INSTITUTE · PI JENNIFER W MACK · 1985 to 2026
$330.6M
NCI NIH HHS P30 CA006516
6 · The paper itself

Abstract

Background Marfan syndrome (MFS) is a genetically transmitted connective tissue disorder characterized by aortic root dilatation, dissection, and rupture. Molecularly, MFS pathological features have been shown to be driven by increased angiotensin II in the aortic wall. Using an angiotensin II-driven aneurysm mouse model, we have recently demonstrated that local inhibition of leptin activity restricts aneurysm formation in the ascending and abdominal aorta. As we observed de novo leptin synthesis in the ascending aortic aneurysm wall of patients with MFS, we hypothesized that local counteracting of leptin activity in MFS may also prevent aortic cardiovascular complications in this context. Methods and Results

Indexed as

AdipokinesAnimalsAortaAortic AneurysmDilatation, PathologicDisease Models, AnimalFibrillin-1Hormone AntagonistsLeptinMaleMarfan SyndromeMice, Mutant StrainsSignal TransductionSystoleVascular RemodelingVentricular Dysfunction, LeftAdipokinesFbn1 protein, mouseFibrillin-1Hormone AntagonistsLeptinaortic aneurysmleptin antagonistlocal therapyMarfan syndromesystolic dysfunction

Identifiers

PMID32378446
PMCPMC7660857
OpenAlexW3020875214

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.